We claim:

A formulation, comprising: an excipient selected from the group consisting of cyclodextrins, liposomes, micelle forming agents, and polymeric carriers; and a compound represented by A:

$$\begin{pmatrix}
R_{6}R_{5}C \\
R_{4}
\end{pmatrix}_{M}$$

wherein

m is 0, 1, 2, 3 or 4;

y is 0, 1, or 2;

R₁ represents alkyl, cycloalkyl, aryl, heteroaryl, aralkyl, or heteroaralkyl;

R₂ represents H, alkyl, cycloalkyl, aryl, heteroaryl, aralkyl, or heteroaralkyl;

R₃ represents H, alkyl, aryl, heteroaryl, OR₂, OC(O)R₂, CH₂OR₂, or CO₂R₂;

R₄ represents H, alkyl, cycloalkyl, alkenyl, cycloalkenyl, aryl, or heteroaryl;


R₅ represents independently for each occurrence H, alkyl, cycloalkyl, aryl, heteroaryl, F, OR₂, or OC(O)R₂;

R₆ represents independently for each occurrence H, alkyl, cycloalkyl, aryl, heteroaryl, F, OR₂, or OC(O)R₂;

any two geminal or vicinal instances of R_5 and R_6 may be connected through a covalent bond; and

the stereochemical configuration at any stereocenter of a compound represented by A is R, S, or a mixture of these configurations.


- 2. The formulation of claim 1, wherein the excipient is a cyclodextrin.
- 3. The formulation of claim 1, wherein m is 2 or 3.
- 4. The formulation of claim 1, wherein m is 2.



- 6. The formulation of claim 1, wherein R_1 represents any or heteroary.
- 7. The formulation of claim 1, wherein R_1 represents aryl.
- 8. The formulation of claim 1, wherein R_2 represents independently for each occurrence alkyl.
- 9. The formulation of claim 1, wherein R, represents H or alkyl.
- 10. The formulation of claim 1, wherein R₃ represents H.
- 11. The formulation of claim 1, wherein R4 represents cycloalkyl, aryl, or heteroaryl.
- 12. The formulation of claim 1, wherein R_4 represents aryl.
- 13. The formulation of claim 1, wherein R_5 represents independently for each occurrence H, or alkyl.
- 14. The formulation of claim 1, wherein R_5 represents independently for each occurrence H.
- 15. The formulation of claim 1, wherein R_6 represents independently for each occurrence H, or alkyl.
- 16. The formulation of claim 1, wherein R_6 represents independently for each occurrence H.

17. The formulation of elain 1, wherein m is 2; and y is 0.

- 18. The formulation of claim 1, wherein m is 2; y is 0, and R₁ represents aryl.
- 19. The formulation of claim 17, wherein m is 2; y is 0; and R₁ represents aryl.
- 20. The formulation of claim 1, wherein m is 2; y is 0; R₁ represents aryl; and R₂ represents independently for each occurrence alkyl.
- 21. The formulation of claim 1, wherein m is 2; y is 0; R₁ represents aryl; R₂ represents independently for each occurrence alkyl; and R₃ represents H.
- 22. The formulation of claim 1, wherein m is 2; y is 0; R₁ represents aryl; R₂ represents independently for each occurrence alkyl; R₃ represents H; and R₄ represents



- 24. The formulation of claim 1, wherein m is 2; y is 0; R_1 represents aryl; R_2 represents independently for each occurrence alkyl; R_3 represents H; R_4 represents aryl; R_5 represents independently for each occurrence H; and R_6 represents independently for each occurrence H.
- 25. The formulation of claim 1, wherein m is 2; y is 0; R_1 represents phenyl; R_2 represents independently for each occurrence ethyl; R_3 represents H; R_4 represents phenyl; R_5 represents independently for each occurrence H; and R_6 represents independently for each occurrence H.
- 26. A method of treating pain, drug addiction, or tinnitus in a mammal, comprising the step of administering to a mammal in need thereof an effective amount of a formulation of claim 1.
- 27. The method of claim 26, wherein said mammal is a primate, equine, canine or feline.
- 28. The method claim 26, wherein said mammal is a human.
- 29. The method of claim 26, 27, or 28, wherein said formulation is administered orally.